Drug
BGB-283 clinical trials
Also written BGB-283.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
3 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BGB-283 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid TumorsCompletedPhase 1BeiGeneNCT03905148Written as Lifirafenib
- Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid TumorsCompletedPhase 1BeiGeneNCT02610361Written as BGB-283
- The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid TumorCompletedPhase 1BeiGeneNCT03641586Written as BGB-283